Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

NCT00616122 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

32

Enrollment

OTHER

Sponsor class

Stopped Risk to benefit ratio not acceptable

Conditions

Breast Cancer

Interventions

DRUG: cyclophosphamide
DRUG: methotrexate
DRUG: sunitinib malate
OTHER: laboratory biomarker analysis

Sponsor

University of California, San Francisco

Collaborators

[object Object]